Skip Navigation LinksHome > October 2011 - Volume 59 - Issue 7 > The Erythropoietin Receptor: Molecular Structure and Hematop...
Journal of Investigative Medicine:
doi: 10.231/JIM.0b013e31820fb28c
EB Symposium Manuscripts

The Erythropoietin Receptor: Molecular Structure and Hematopoietic Signaling Pathways

Watowich, Stephanie S. PhD

Free Access
Article Outline
Collapse Box

Author Information

From the Department of Immunology and Center for Inflammation and Cancer, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, and The Graduate School of Biomedical Sciences, The University of Texas, Houston, TX.

Received November 15, 2010, and in revised form January 3, 2011.

Accepted for publication January 4, 2011.

Supported in part by a grant from the National Center for Research Resources (R13 RR023236). Unrelated work in the author's laboratory is supported by an Investigator-initiated Preclinical Research Agreement with Amgen, Inc., grants from the National Institutes of Health (AI073587 and AR059010) and a seed grant from the Center for Stem Cell and Developmental Biology at University of Texas M. D. Anderson Cancer Center.

Reprints: Stephanie S. Watowich, PhD, Department of Immunology, The University of Texas M. D. Anderson Cancer Center, P.O. Box 301402, Unit 902, Houston, TX 77030-1903. E-mail: swatowic@mdanderson.org.

Collapse Box

Abstract

The process of erythropoiesis in the fetal liver and adult bone marrow is regulated by the hormone erythropoietin (Epo), which is produced in the kidney at low levels under homeostatic conditions. Defects in Epo production result in severe anemia; use of recombinant hormone has improved the lives of patients with renal failure or anemia because of bone marrow suppression. Deletion of the Epo gene in mice leads to embryonic lethality at days 13 to 15, coincident with the establishment of definitive (adult-type) erythropoiesis and underscoring the absolute necessity of Epo function in vivo. Epo has proven to be a successful pharmaceutical agent, one of the early triumphs of recombinant protein technology. Because of its clinical importance, a great deal of attention has focused on the molecular mechanisms of Epo-regulated erythropoiesis. This review highlights the basic concepts of Epo signal transduction within the hematopoietic system, the major site of Epo action in vivo.

Epo is present in low amounts in the circulation under homeostatic conditions, whereas erythropoietic stress, such as hypoxia or anemia, can stimulate a dramatic increase in Epo production in the kidney, leading to a significant rise in circulating hormone amounts and subsequently increased erythropoiesis.1-3 Epo stimulates red blood cell production by binding and activating a high affinity receptor (EpoR) that is expressed predominantly on the surface of immature erythroid cells.4 The EpoR is a member of the type I cytokine receptor superfamily, sharing specific structural motifs with other members of this receptor family including 2 extracellular immunoglobulin-like domains, 4 similarly spaced cysteine residues, and the sequence WSXWS.5,6 Signal transduction through the EpoR is initiated by ligand binding, which induces a dimerization and/or reorientation of EpoR monomers within a dimeric receptor structure,7-11 a process that remains poorly understood despite its clear importance in terms of developing Epo agonists. The general mechanisms used by EpoR to activate intracellular signal transduction pathways are shared by other members of the types I and II cytokine receptor families, namely ligand-dependent oligomerization and/or structural reorientation of clustered receptor molecules.12 The predominant pathway activated by EpoR and other cytokine receptors is the Jak/STAT signaling cascade.12-14 Jak tyrosine kinases are constitutively associated with the membrane-proximal regions of cytokine receptor intracellular domains and are activated upon ligand binding and receptor reorientation. The EpoR associates selectively with the Jak2 kinase.15 After EpoR activation, Jak2 phosphorylates tyrosine residues in the intracellular region of the EpoR, providing docking sites for signaling molecules with phosphotyrosine binding motifs, including the signal transducer and activator of transcription protein STAT5, which mediates the principal intracellular signaling pathway elicited by the EpoR16,17 (Fig. 1). Here, I will discuss EpoR structural features and mechanisms of EpoR signal transduction via Jak2 and STAT5 that regulate erythropoiesis.

Figure 1
Figure 1
Image Tools
Back to Top | Article Outline
Role of Dimerization in EpoR Activation

The activation mechanism for EpoR was elucidated first through investigation of a constitutively acting (hormone-independent) form of the EpoR, which was isolated from a retroviral transduction screen in the interleukin 3-dependent murine cell line Ba/F3 by virtue of its ability to support cytokine-independent proliferation.18 Initially, the biochemical basis for the constitutive activity was unclear; however, a point mutation at residue 129 in the extracellular region that rendered an arginine to cysteine substitution (EpoR R129C)18 suggested the possibility that aberrant disulfide bond formation was involved. The constitutive activity of EpoR R129C is attributed to acquisition of cysteine and not loss of arginine.11 Moreover, EpoR R129C but not the wild-type receptor forms disulfide-linked homodimers in the absence of Epo.10,11 These data collectively implicate dimerization as an important feature of the EpoR activation mechanism. Studies with the constitutive EpoR provided a paradigm for the process of types I and II cytokine receptor activation because it was subsequently recognized that oligomerization or structural reorientation of receptor subunits was a common activation mechanism within the cytokine receptor family.12,19,20

Equilibrium binding experiments with iodinated Epo demonstrated that Epo:receptor complexes containing either wild-type EpoR or EpoR R129C were governed by a single affinity (dissociation constant, ∼100-700 pM),4,11,21 indicating that the 3-dimensional structure of EpoR R129C is similar to the wild-type receptor, at least within the Epo-binding domain. This suggested that covalent dimerization of EpoR R129C mimics the Epo/EpoR conformation, further supporting a role for receptor dimerization in the activation process. To determine whether the signals elicited by EpoR R129C are similar to or distinct from the ligand-occupied wild-type receptor, the ability of EpoR R129C to support erythropoiesis was assessed. EpoR R129C stimulates Epo-independent colony forming unit-erythroid (CFU-E) development, as judged by ex vivo assays,22,23 indicating that it supports erythroid proliferation and differentiation. Moreover, mice infected with retrovirus carrying EpoR R129C develop erythrocytosis and splenomegaly and show increased amounts of circulating red blood cells,24,25 demonstrating that EpoR R129C stimulates expansion of the erythroid compartment in vivo and indicating deregulation of homeostatic mechanisms most likely due to constitutive signaling of EpoR R129C. Thus, EpoR R129C seems to mimic the biological activity of the Epo:EpoR complex in terms of directing proliferation and differentiation of red blood cell precursors, without perturbing the erythroid developmental program. Interestingly, overexpression of EpoR R129C in hematopoietic progenitor cells can enhance the generation of other myeloid lineages,22,23,25 early evidence that suggested redundancy in the signal pathways between blood cell growth factors.

Several methods have been used to test the hypothesis that the wild-type EpoR is active as a dimer at the cell surface, upon ligand binding. Biochemical assays to probe for EpoR dimers using covalent cross-linking agents were largely unsuccessful.26 This is most likely due to the low cell surface expression of the receptor and specific features of the EpoR extracellular region, such as the presence of only 3 lysine residues (K10, K14, K65 in the human; K10, K14, K64 in the murine EpoR) located distal to all binding interfaces,9,27 which would be substrates for many of the cross-linkers available. However, studies with coexpressed wild-type and carboxy-terminally truncated EpoRs demonstrated that mutant EpoRs exhibited dominant inhibitory activity, suggestive of interactions with the wild-type EpoR that interfere with receptor signaling.10,28 Moreover, EpoR dimerization by bivalent antibodies, analysis of chimeric receptor molecules, or biochemical studies of the purified EpoR extracellular region further supported the idea that receptor clustering is an important step in the activation process.8,29-31 The most definitive evidence for receptor dimerization was obtained by 3-dimensional structure analyses of the EpoR extracellular region bound to Epo or erythropoietic peptide agonists.9,27 The EpoR:Epo complex is a dimeric receptor occupied by a single Epo molecule in a 2:1 EpoR:Epo ratio.9 These data indicate the strong likelihood for a dimeric receptor structure as the principal EpoR signaling complex. Evidence from EpoR R129C metabolic pulse-chase labeling experiments, showing intracellular disulfide-linked dimers, as well as structural analyses of the EpoR extracellular region without bound ligand, suggest the EpoR dimer forms during receptor synthesis within the cell.7,11 Hence, dimeric EpoRs seem to be transported to the plasma membrane, where ligand activation induces a conformational change in the orientation of receptor subunits within the dimer.

The quaternary structure of the EpoR has important implications for hematopoiesis in humans as it suggests that EpoR-mediated signal transduction could be altered in individuals with heterozygous mutation of the EpoR gene resulting from inherited or acquired events.32-37 Individuals from an extended Finnish family with dominant benign familial erythrocytosis provide such an example; fortunately, in this instance, the phenotype is mild. Certain individuals within this Finnish family were found to have enhanced erythrocytosis, accompanied by increased hematocrits and hemoglobin amounts.34,35 Erythroid progenitor cells isolated from these individuals demonstrate hypersensitivity to Epo in culture, as judged by their ability to undergo effective proliferation and differentiation in reduced Epo amounts ex vivo, compared with progenitor cells from unaffected individuals.34,35 The individuals exhibiting erythrocytosis possess a mutation in one copy of the EpoR gene, which generates a premature stop codon and truncated receptor isoform lacking approximately 70 amino acids from the carboxy-terminus.35 This truncated EpoR is missing an important negative regulatory region in the cytoplasmic domain that is responsible for recruitment of hematopoietic cell phosphatase 1, which has been shown to suppress signaling from the EpoR as well as other cytokine receptors upon its association with activated receptor complexes.38-42 Assuming both wild-type and mutant EpoR alleles are coexpressed in individuals with erythrocytosis, these individuals may express different EpoR complexes versus those with only wild-type EpoR. The EpoR complexes may include homodimers of the truncated EpoR and heterodimers of wild-type and mutant EpoRs, which may alter receptor signal transduction resulting in hypersensitivity to Epo and mild erythrocytosis. Coexpression of wild-type and truncated EpoRs in tissue culture cells validated this model. Cytokine-dependent cells that were engineered to express both wild-type and truncated EpoRs mimicking the Finnish mutation, or a similarly truncated EpoR expressed in affected members of a Swedish family with dominant erythrocytosis, exhibited enhanced Epo-mediated signal transduction and cellular proliferation compared with cells expressing only wild-type EpoR.37 In both Finnish and Swedish families, the EpoR mutation seems to be inherited with Mendelian frequencies.34,35,37 Moreover, the EpoR mutation functions in a dominant manner relative to the wild-type allele of the EpoR gene.34,35,37 These data are collectively indicative of association between coexpressed mutant and wild-type EpoRs and subsequent enhancement of EpoR signal transduction.

Back to Top | Article Outline
Molecular Structure of the EpoR

The 3-dimensional structure of the EpoR extracellular region was first determined at 2.8 Å resolution in complex with the agonist peptide EMP127 and later in complex with Epo at 1.9 Å resolution.9 Both approaches showed that the EpoR extracellular region comprises 2 immunoglobulin-like domains, each formed by a β-sandwich-like structure containing 7 β-strands. The membrane-distal (D1) domain and membrane-proximal (D2) domain are linked by a short hinge and are oriented at approximately 90 degrees to one another (Fig. 1). The D1 domain contains the 4 conserved cysteine residues, which form 2 intramolecular disulfide bridges that stabilize D1,9,27 whereas D2 contains the conserved WSXWS motif. As predicted from saturation mutagenesis experiments of the EpoR WSXWS motif, this motif seems to stabilize the EpoR tertiary structure.9,27,43

The EpoR:Epo complex revealed that Epo has 2 discrete binding sites for the EpoR.9 One binding interface of the ligand governs a high affinity interaction with the receptor, comprising a hydrophobic core surrounded by hydrophilic residues, a motif that has been referenced as a "hot spot" in terms of directing cytokine:cytokine receptor interactions.44 The high affinity site exhibits a dissociation constant of approximately 1 nM and is thought to contribute the majority of the ligand binding energy.9 A second binding site that uses a distinct set of determinant residues on Epo as well as EpoR has an affinity approximately 1000-fold lower (dissociation constant of ∼1 μM).8 Thus, a sequential binding model for ligand-mediated activation of EpoR has been proposed, in which ligand interacts first via the high affinity site with one receptor chain and then through the low affinity interaction with the second EpoR monomer.45 Despite the asymmetry of this complex, both monomers seem to be functionally similar in terms of activating signal transduction.46 Moreover, interactions between the transmembrane and membrane-proximal cytoplasmic domains of EpoR monomers facilitate dimerization and/or stabilization of the EpoR dimeric complex.47-50 The importance of the asymmetric complex and the dimerization model of receptor activation is supported by the observation that an Epo molecule mutated in the "site 2" region (R103A) or EpoRs mutated at the binding region for Epo "site 1" or "site 2" fail to elicit receptor signaling in hematopoietic cells.45,46 The Epo R103A mutant also has provided an opportunity to characterize the EpoR complex on nonhematopoietic cells. Cytoprotective activities of Epo on the differentiated neuroblastoma SH-SY5Y cell line were suppressed considerably with Epo R103A or via RNA-mediated interference of EpoR expression,51 indicating that survival signaling elicited by Epo on neuronal cells is most likely due to low levels of the EpoR expressed in the configuration of the hematopoietic receptor (i.e., EpoR homodimer).

The dimeric EpoR structures formed by interaction with Epo or the EMP1 agonist differ in several aspects, likely explaining the fact that EMP1 exhibits reduced potency in terms of EpoR activation, as EMP1 is required at significantly higher concentrations than Epo to elicit erythropoietic responses.9,27 The angle between the D1 domains differs in each EpoR:ligand complex (∼120 degrees in the EpoR:Epo complex versus ∼180 degrees in the EpoR:EMP1 complex). Moreover, the EpoR:Epo complex shows the D2 domains positioned within the same plane while they are twisted at an approximate 45-degree angle in the EpoR:EMP1 structure.9,27 This distinction may affect the ability to activate the associated Jak2 kinase, as a particular orientation may be favored for full Jak2 activation via autophosphorylation. Hence, efficient Epo agonists will likely need to more closely mimic the ligand-occupied receptor orientation.

Back to Top | Article Outline
Roles for EpoR-Mediated Jak2 and STAT5 Signaling in Erythropoiesis

One of the earliest detectable signaling events elicited upon EpoR activation is tyrosine phosphorylation of several intracellular proteins.52,53 Because the receptor lacks a kinase domain within its cytoplasmic region, these results indicated that protein tyrosine kinase function is carried out by a distinct factor. Subsequently, the Jak2 protein tyrosine kinase was identified as associating with the EpoR and serving as the principal kinase involved in mediating Epo-responsive signal transduction.15,53,54 Jak2 is constitutively bound to the EpoR intracellular region (Fig. 1) and seems to provide a chaperone function for newly assembled EpoR molecules, aiding their transit through the secretory pathway from the endoplasmic reticulum to the plasma membrane.55 Deletion of the Jak2 gene in mice causes embryonic lethality at d 12-13 accompanied by severe anemia.56 The phenotype of Jak2−/− animals closely resembles the Epo−/− or Epor−/− mice56,57; hematopoietic progenitors from Jak2−/− fetal livers are deficient in responses to Epo, indicating Jak2 is essential for Epo-dependent definitive erythropoiesis.56 Jak2−/− hematopoietic progenitors also fail to respond to other myeloid cytokines, such as granulocyte macrophage colony-stimulating factor and interleukin 356; hence, the embryonic lethality of Jak2−/− animals most likely represents the first essential role for Jak2 during development but not all aspects of Jak2 function in vivo.

Significantly, Jak2 function is important in human erythropoiesis. A mutation within the Jak2 pseudokinase domain rendering a valine to phenylalanine substitution at residue 617 (V617F) and hormone-independent kinase activity was identified in individuals with a spectrum of myeloproliferative disorders (MPDs) including polycythemia vera.58-60 In vitro and in vivo approaches to study Jak2 V617F show that this mutant protein mediates Epo-independent erythroid progenitor growth and development as well as erythroid cell expansion in vivo.59,61 Jak2 is therefore a feasible target for pharmacological intervention as a new approach for treatment of Jak2 V617F-positive MPDs.

The EpoR contains 8 tyrosine residues within the membrane-distal portion of cytoplasmic tail; upon phosphorylation, several of these serve as docking sites for intracellular signaling molecules, including the transcription factors STAT5A and STAT5B, the p85 subunit of phosphoinositol 3'-kinase (PI3K), the cytokine suppressor CIS, and the phosphatase SHP-1.40,62-71 Tyrosine-phosphorylated Jak2 also seems to interact directly with STAT5A and STAT5B,72 indicating that it can serve as a scaffold for signal protein activation in addition to its enzymatic role in EpoR signal transduction. Recruitment of signaling molecules in proximity to Jak2 in the EpoR complex enables their tyrosine phosphorylation, which is an important step in subsequent activation of their respective signaling cascades (Fig. 1). The STAT5A and STAT5B proteins are predominant signal transducers for EpoR16,17,65,68,71; these proteins are activated within seconds of Epo binding and accumulate in the nucleus to mediate Epo-responsive transcription.

The first report of mice deficient in both STAT5A and STAT5B indicated that STAT5 activity was nonessential for adult erythropoiesis in homeostatic conditions, evidenced by a normal hematocrit in mice with targeted gene disruption.73 However, STAT5 deficiency was found to cause a severe effect on fetal erythropoiesis, which proceeds at a high rate in the liver during gestation,17 as well as adult red blood cell formation during erythropoietic stress,74 indicating a critical role for STAT5 in demand-driven erythropoiesis. These studies showed that STAT5 operates by regulating erythroid survival and highlighted a key mechanism via STAT5-mediated control of the survival gene BclXL.17,74 It was later determined that the original STAT5-deficient animals corresponded to a hypomorphic STAT5 model (Stat5abΔN/ΔN), in which an N-terminally truncated STAT5 protein is detectable within certain cell types.75 The Stat5abΔN/ΔN mice have been a valuable resource for understanding STAT5 structure-function relationships in vivo and have revealed critical roles for the STAT5 N-domain in mechanisms such as leukemia progression.75 However, because Stat5abΔN/ΔN mice are not completely deficient in STAT5 function, work in this model could not definitively delineate the role for STAT5 in red blood cell development. Fortunately, a complete Stat5a−/− Stat5b−/− knockout mouse model was developed within Dr. Lothar Hennighausen's laboratory.16 Stat5a−/− Stat5b−/− mice exhibit severe anemia, as judged by significantly reduced hematocrits compared with wild-type littermates.16 Stat5a−/− Stat5b−/− mice have a perinatal lethality, although this is not thought to be a consequence of the severe anemia as a small proportion of Stat5a−/− Stat5b−/− are able to survive despite low red blood cell numbers. Thus, STAT5 serves an essential role in controlling erythropoiesis in vivo.

Back to Top | Article Outline
Summary and Future Perspectives

The EpoR has provided a paradigm for understanding cytokine receptor structure and signal transduction, as well as cytokine function in normal and aberrant hematopoiesis.76-80 Functioning as a dimeric molecule, the ligand-occupied receptor activates the Jak2 protein tyrosine kinase, which in turn phosphorylates tyrosine residues on the receptor and associated intracellular signaling molecules (Fig. 1). STAT5 is a principal signaling protein activated upon receptor ligation, and its function is essential for normal red blood cell development in vivo. Although mutations in Jak2 have been identified in MPDs and leukemia, it is not yet clear if STAT5 mutations are associated with human disease. However, persistently activated STAT5 is found in many hematological cancers,81-83 and thus, a greater understanding of STAT5-mediated signaling cascades is necessary to reveal molecular mechanisms that may contribute to disease. Moreover, other signaling cascades, such as the PI3K/Akt and Ras/MAPK pathways, are elicited upon EpoR activation and seem to play a role in erythropoiesis as judged by studies with primary red cell progenitors ex vivo or hematopoietic cell lines69,84-92; however, we have limited knowledge of the function of these signaling responses during steady-state and stress erythropoiesis because of the lack of appropriate genetic mouse models. Future work should include dissection of non-Jak-STAT signaling cascades in the erythropoietic response.

Back to Top | Article Outline

ACKNOWLEDGMENTS

The author thanks Hoainam Nguyen-Jackson, for critical review of the manuscript, and members of the Watowich laboratory at M. D. Anderson, for advice and discussion.

Back to Top | Article Outline

REFERENCES

1. Koury ST, Koury MJ, Bondurant MC, et al. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood. 1989;74:645-651.

2. Lacombe C, Da Silva JL, Bruneval P, et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest. 1988;81:620-623.

3. Krantz SB. Erythropoietin. Blood. 1991;77:419-434.

4. Broudy VC, Lin N, Brice M, et al. Erythropoietin receptor characteristics on primary human erythroid cells. Blood. 1991;77:2583-2590.

5. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A. 1990;87:6934-6938.

6. Cosman D, Lyman SD, Idzerda RL, et al. A new cytokine receptor superfamily. Trends Biochem Sci. 1990;15:265-270.

7. Livnah O, Stura EA, Middleton SA, et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999;283:987-990.

8. Philo JS, Aoki KH, Arakawa T, et al. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry. 1996;35:1681-1691.

9. Syed RS, Reid SW, Li C, et al. Efficiency of signaling through cytokine receptors depends critically on receptor orientation. Nature. 1998;395:511-516.

10. Watowich SS, Hilton DJ, Lodish HF. Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. Mol Cell Biol. 1994;14:3535-3549.

11. Watowich SS, Yoshimura A, Longmore GD, et al. Homodimerization and constitutive activation of the erythropoietin receptor. Proc Natl Acad Sci U S A. 1992;89:2140-2144.

12. Hibi M, Hirano T. Signal transduction through cytokine receptors. Int Rev Immunol. 1998;17:75-102.

13. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415-1421.

14. Darnell JE Jr. STATs and gene regulation. Science. 1997;277:1630-1635.

15. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993;74:227-236.

16. Cui Y, Riedlinger G, Tang W, et al. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol. 2004;24:8037-8047.

17. Socolovsky M, Fallon AE, Wang S, et al. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell. 1999;98:181-191.

18. Yoshimura A, Longmore G, Lodish HF. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature. 1990;348:647-649.

19. Foxwell BM, Barrett K, Feldmann M. Cytokine receptors: structure and signal transduction. Clin Exp Immunol. 1992;90:161-169.

20. Ihle JN, Witthuhn BA, Quelle FW, et al. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol. 1995;13:369-398.

21. Mayeux P, Billat C, Jacquot R. Murine erythroleukaemia cells (Friend cells) possess high-affinity binding sites for erythropoietin. FEBS Lett. 1987;211:229-233.

22. Longmore GD, Pharr PN, Lodish HF. A constitutively activated erythropoietin receptor stimulates proliferation and contributes to transformation of multipotent, committed nonerythroid and erythroid progenitor cells. Mol Cell Biol. 1994;14:2266-2277.

23. Pharr PN, Hankins D, Hofbauer A, et al. Expression of a constitutively active erythropoietin receptor in primary hematopoietic progenitors abrogates erythropoietin dependence and enhances erythroid colony-forming unit, erythroid burst-forming unit, and granulocyte/macrophage progenitor growth. Proc Natl Acad Sci USA. 1993;90:938-942.

24. Longmore GD, Lodish HF. An activating mutation in the murine erythropoietin receptor induces erythroleukemia in mice: a cytokine receptor superfamily oncogene. Cell. 1991;67:1089-1102.

25. Longmore GD, Pharr P, Neumann D, et al. Both megakaryocytopoiesis and erythropoiesis are induced in mice infected with a retrovirus expressing an oncogenic erythropoietin receptor. Blood. 1993a;82:2386-2395.

26. Watowich SS, Hilton DJ. (1992). Unpublished results.

27. Livnah O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science. 1996;273:464-471.

28. Barber DL, DeMartino JC, Showers MO, et al. A dominant negative erythropoietin (epo) receptor inhibits epo-dependent growth and blocks F-gp55-dependent transformation. Mol Cell Biol. 1994;14:2257-2265.

29. Elliot S, Lorenzini T, Yanagihara D, et al. Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies. J Biol Chem. 1996;271:24691-24697.

30. Schneider H, Chaovapong W, Matthews DJ, et al. Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. Blood. 1997;89:473-482.

31. Watowich SS, Liu KD, Xie X, et al. Oligomerization and scaffolding functions of the erythropoietin receptor cytoplasmic tail. J Biol Chem. 1999a;274:5415-5421.

32. Arcasoy MO, Degar BA, Harris KW, et al. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood. 1997;89:4628-4635.

33. Arcasoy MO, Karayal AF, Segal HM, et al. A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis. Blood. 2002;99:3066-3069.

34. de la Chapelle A, Sistonen P, Lehvaslaiho H, et al. Familial erythrocytosis genetically linked to erythropoietin receptor gene. Lancet. 1993a;341:82-84.

35. de la Chapelle A, Traskelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A. 1993b;90:4495-4499.

36. Kralovics R, Indrak K, Stopka T, et al. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood. 1997;90:2057-2061.

37. Watowich SS, Xie X, Klingmuller U, et al. Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state. Blood. 1999b;94:2530-2532.

38. D'Andrea AD, Yoshimura A, Youssoufian H, et al. The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol. 1991;11:1980-1987.

39. Jiao H, Yang W, Berrada K, et al. Macrophages from motheaten and viable motheaten mutant mice show increased proliferative responses to GM-CSF: detection of potential HCP substrates in GM-CSF signal transduction. Exp Hematol. 1997;25:592-600.

40. Klingmuller U, Lorenz U, Cantley LC, et al. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell. 1995;80:729-738.

41. Tapley P, Shevde NK, Schweitzer PA, et al. Increased G-CSF responsiveness of bone marrow cells from hematopoietic cell phosphatase deficient viable motheaten mice. Exp Hematol. 1997;25:122-131.

42. Yi T, Mui AL, Krystal G, et al. Hematopoietic cell phosphatase associates with the interleukin-3 (IL-3) receptor beta chain and down-regulates IL-3-induced tyrosine phosphorylation and mitogenesis. Mol Cell Biol. 1993;13:7577-7586.

43. Hilton DJ, Watowich SS, Katz L, et al. Saturation mutagenesis of the WSXWS motif of the erythropoietin receptor. J Biol Chem. 1996;271:4699-4708.

44. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science. 1995;267:383-386.

45. Matthews DJ, Topping RS, Cass RT, et al. A sequential dimerization mechanism for erythropoietin receptor activation. Proc Natl Acad Sci USA. 1996;93:9471-9476.

46. Zhang YL, Radhakrishnan ML, Lu X, et al. Symmetric signaling by an asymmetric 1 erythropoietin: 2 erythropoietin receptor complex. Mol Cell. 2009;33:266-274.

47. Constantinescu SN, Keren T, Socolovsky M, et al. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A. 2001;98:4379-4384.

48. Gurezka R, Laage R, Brosig B, et al. A heptad motif of leucine residues found in membrane proteins can drive self-assembly of artificial transmembrane segments. J Biol Chem. 1999;274:9265-9270.

49. Kubatzky KF, Ruan W, Gurezka R, et al. Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Curr Biol. 2001;11:110-115.

50. Seubert N, Royer Y, Staerk J, et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell. 2003;12:1239-1250.

51. Um M, Gross AW, Lodish HF. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal. 2007;19:634-645.

52. Miura O, D'Andrea AD, Kabat D, et al. Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis. Mol Cell Biol. 1991;11:4895-4902.

53. Yoshimura A, Lodish HF. In vitro phosphorylation of the erythropoietin receptor and an associated protein, pp130. Mol Cell Biol. 1992;12:706-715.

54. Miura O, Nakamura N, Quelle FW, et al. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo. Blood. 1994;84:1501-1507.

55. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell. 2001;8:1327-1338.

56. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93:385-395.

57. Wu H, Liu X, Jaenisch R, et al. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83:59-67.

58. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.

59. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.

60. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.

61. Zaleskas VM, Krause DS, Lazarides K, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One. 2006;1:e18.

62. Chin H, Nakamura N, Kamiyama R, et al. Physical and functional interactions between Stat5 and the tyrosine-phosphorylated receptors for erythropoietin and interleukin-3. Blood. 1996;88:4415-4425.

63. Damen Je, Cutler RL, Jiao H, et al. Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity. J Biol Chem. 1995a;270:23402-23408.

64. Damen JE, Mui AL, Puil L, et al. Phosphatidylinositol 3-kinase associates, via its Src homology 2 domains, with the activated erythropoietin receptor. Blood. 1993;81:3204-3210.

65. Damen JE, Wakao H, Miyajima A, et al. Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. EMBO J. 1995b;14:5557-5568.

66. Gobert S, Chretien S, Gouilleux F, et al. Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for Stat5 activation. EMBO J. 1996;15:2434-2441.

67. Iwatsuki K, Endo T, Misawa H, et al. STAT5 activation correlates with erythropoietin receptor-mediated erythroid differentiation of an erythroleukemia cell line. J Biol Chem. 1997;272:8149-8152.

68. Klingmuller U, Bergelson S, Hsiao JG, et al. Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5. Proc Natl Acad Sci U S A. 1996;93:8324-8328.

69. Klingmuller U, Wu H, Hsiao JG, et al. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci U S A. 1997;94:3016-3021.

70. Matsumoto A, Masuhara M, Mitsui K, et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 1997;89:3148-3154.

71. Wakao H, Harada N, Kitamura T, et al. Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways. EMBO J. 1995;14:2527-2535.

72. Fujitani Y, Hibi M, Fukada T, et al. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT. Oncogene. 1997;14:751-761.

73. Teglund S, McKay C, Schuetz E, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998;93:841-850.

74. Socolovsky M, Nam H, Fleming MD, et al. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood. 2001;98:3261-3273.

75. Moriggl R, Sexl V, Kenner L, et al. Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell. 2005;7:87-99.

76. Goyal RK, Longmore GD. Abnormalities of cytokine receptor signalling contributing to diseases of red blood cell production. Ann Med. 1999;31:208-216.

77. Longmore GD, Watowich SS, Hilton DJ, et al. The erythropoietin receptor: its role in hematopoiesis and myeloproliferative diseases. J Cell Biol. 1993b;123:1305-1308.

78. Socolovsky M. Molecular insights into stress erythropoiesis. Curr Opin Hematol. 2007;14:215-224.

79. Watowich SS, Wu H, Socolovsky M, et al. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu Rev Cell Dev Biol. 1996;12:91-128.

80. Wojchowski DM, Gregory RC, Miller CP, et al. Signal transduction in the erythropoietin receptor system. Exp Cell Res. 1999;253:143-156.

81. Benekli M, Baer MR, Baumann H, et al. Signal transducer and activator of transcription proteins in leukemias. Blood. 2003;101:2940-2954.

82. Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol. 2009;27:4422-4432.

83. Sternberg DW, Gilliland DG. The role of signal transducer and activator of transcription factors in leukemogenesis. J Clin Oncol. 2004;22:361-371.

84. Carroll MP, Spivak JL, McMahon M, et al. Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation. J Biol Chem. 1991;266:14964-14969.

85. Ghaffari S, Kitidis C, Zhao W, et al. AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood. 2006;107:1888-1891.

86. Gobert S, Duprez V, Lacombe C, et al. The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells. Eur J Biochem. 1995;234:75-83.

87. Haseyama Y, Sawada K, Oda A, et al. Phosphatidylinositol 3-kinase is involved in the protection of primary cultured human erythroid precursor cells from apoptosis. Blood. 1999;94:1568-1577.

88. Nagata Y, Moriguchi T, Nishida E, et al. Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3. Blood. 1997a;90:929-934.

89. Nagata Y, Nishida E, Todokoro K. Activation of JNK signaling pathway by erythropoietin, thrombopoietin, and interleukin-3. Blood. 1997b;89:2664-2669.

90. Nagata Y, Todokoro K. Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. Blood. 1999;94:853-863.

91. Shan R, Price JO, Gaarde WA, et al. Distinct roles of JNKs/p38 MAP kinase and ERKs in apoptosis and survival of HCD-57 cells induced by withdrawal or addition of erythropoietin. Blood. 1999;94:4067-4076.

92. Zhao W, Kitidis C, Fleming MD, et al. Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood. 2006;107:907-915.

Cited By:

This article has been cited 2 time(s).

Biochimica Et Biophysica Acta-Molecular Basis of Disease
Erythropoietin is a hypoxia inducible factor-induced protective molecule in experimental autoimmune neuritis
Luo, BW; Jiang, M; Yang, XF; Zhang, ZY; Xiong, J; Schluesener, HJ; Zhang, ZR; Wu, YZ
Biochimica Et Biophysica Acta-Molecular Basis of Disease, 1832(8): 1260-1270.
10.1016/j.bbadis.2013.04.015
CrossRef
Molecular and Cellular Endocrinology
Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes
Pan, Y; Shu, JL; Gu, HF; Zhou, DC; Liu, XL; Qiao, QY; Fu, SK; Gao, FH; Jin, HM
Molecular and Cellular Endocrinology, 367(): 116-123.
10.1016/j.mce.2012.12.027
CrossRef
Back to Top | Article Outline
Keywords:

Erythropoietin; receptor; Jak; STAT

© 2011 American Federation for Medical Research

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.